NK cell mobilization as a pathogenic etiology of SARS-CoV-2 gastrointestinal disease

NK 细胞动员作为 SARS-CoV-2 胃肠道疾病的致病病因

基本信息

  • 批准号:
    10626025
  • 负责人:
  • 金额:
    $ 40.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of Coronavirus Disease 2019 (COVID-19) and its rapid global spread has led to an unprecedented global public health crisis. Currently, treatment options are very limited and vaccines against SARS-CoV-2 are still pending widespread use. Host immune responses to SARS-CoV-2 play a crucial role in the containment of the infection. Although SARS-CoV-2 is generally thought of as a respiratory disease, an unexpected consequence is severe complications of the gastrointestinal tract (GIT). Indeed, up to two-thirds of COVID-19 patients have some GIT symptoms and several lines of evidence suggest a breakdown of the epithelial barrier resulting in widespread inflammation. While recent studies in COVID-19 patients and nonhuman primate (NHP) models described T lymphocytes and antibody responses, less is known about natural killer (NK) cell responses in SARS-CoV-2 infection. Classically, NK cells are viewed as nonspecific effector cells of the innate immune system that play critical roles in defense against viral infections. However, besides their ability to rapidly eliminate virus-infected cells without the need for prior antigen sensitization, NK cells also exhibit adaptive immune functions. Different forms of adaptive capabilities have been identified among human NK cell subpopulations, including reports of true antigen-specific memory NK cells as well as adaptive NK cells with enhanced antibody-dependent functions. NK cells may be crucial for early containment of SARS-CoV-2 and formation of adaptive responses elicited by infection, yet uncontrolled NK response may also contribute to the hyperinflammatory responses observed in COVID-19 patients, including in the GIT. In this proposal we will use NHP models, which recapitulate viral replication, immune responses and disease pathology observed in human COVID-19 infection, to test the following hypotheses: (i) pathogenic inflammation in the gastrointestinal tract in COVID-19 is a consequence, in part, of dysregulated or exacerbated NK cell responses, and (ii) specific subsets of NK cells mediate potent anti-viral responses against SARS-CoV-2, associated with enhanced viral clearance and reduced disease severity. We will address these hypotheses through two specific aims: 1. Determine the contribution of systemic and GIT NK cell mobilization to SARS-CoV-2 pathogenesis and clearance in macaque models; 2. Evaluate the mechanisms by which specific innate and adaptive NK cell subpopulations modulate SARS-CoV-2 infection in the GIT. If successful, the results of these innovative studies will contribute new knowledge of human immune responses against SARS-CoV-2 and provide the rationale to develop novel immunotherapeutic approaches to target specific NK cell subsets that could substantially contribute to prevent and treat COVID-19.
严重的急性呼吸综合征冠状病毒2(SARS-COV-2)是冠状病毒的病因学药 2019年疾病(Covid-19)及其快速的全球差异导致了前所未有的全球公共卫生危机。 目前,治疗方案非常有限,针对SARS-COV-2的疫苗仍在待定 使用。宿主对SARS-COV-2的免疫反应在控制感染中起着至关重要的作用。虽然 SARS-COV-2通常被认为是一种呼吸道疾病,意外后果是严重的 胃肠道(GIT)的并发症。实际上,多达三分之二的Covid-19患者有一些git 症状和几条证据表明上皮屏障的崩溃,导致广泛 炎。 虽然最近对199名患者和非人类灵长类动物(NHP)模型的研究描述了T淋巴细胞 和抗体反应,对SARS-COV-2感染中的天然杀伤(NK)细胞反应知之甚少。 从经典上讲,NK细胞被视为先天免疫系统的非特异性效应细胞,起着关键作用 防御病毒感染。但是,除了它们能够快速消除没有病毒感染的细胞的能力之外 需要先前的抗原敏化,NK细胞也表现出适应性免疫功能。不同形式的 在人类NK细胞亚群中已经确定了自适应能力,包括真实的报告 抗原特异性记忆NK细胞以及具有增强抗体依赖性功能的自适应NK细胞。 NK 细胞可能对早期遏制SARS-COV-2和形成自适应反应至关重要 感染,但不受控制的NK反应也可能导致在 COVID-19患者,包括GIT。在此提案中,我们将使用NHP模型,该模型概括病毒 在人类联盟19感染中观察到的复制,免疫反应和疾病病理,以测试 以下假设:(i)胃肠道中的致病性炎症是19 结果部分是失调或恶化的NK细胞响应,以及(ii)NK的特定子集 细胞介导针对SARS-COV-2的有效抗病毒反应,与增强的病毒清除有关 并降低了疾病的严重程度。我们将通过两个具体目标解决这些假设:1。确定 全身和GIT NK细胞动员对猕猴中SARS-COV-2发病机理的贡献 模型; 2。评估特定先天和自适应NK细胞亚群调节的机制 git中的SARS-COV-2感染。如果成功,这些创新研究的结果将有助于新 对人类免疫反应对SARS-COV-2的了解,并提供了发展新颖的理由 免疫治疗方法靶向特定的NK细胞子集,这可能有助于防止 并治疗Covid-19。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roger Keith Reeves其他文献

Roger Keith Reeves的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roger Keith Reeves', 18)}}的其他基金

Microbial and innate immune mechanisms of oral inflammation during SIV infection
SIV感染期间口腔炎症的微生物和先天免疫机制
  • 批准号:
    10408915
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
NK cell mobilization as a pathogenic etiology of SARS-CoV-2 gastrointestinal disease
NK 细胞动员作为 SARS-CoV-2 胃肠道疾病的致病病因
  • 批准号:
    10319735
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Mechanisms of Natural Killer Cell Clearance of SIV from Lymphoid Follicles
淋巴滤泡自然杀伤细胞清除 SIV 的机制
  • 批准号:
    10408913
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
NK cell mobilization as a pathogenic etiology of SARS-CoV-2 gastrointestinal disease
NK 细胞动员作为 SARS-CoV-2 胃肠道疾病的致病病因
  • 批准号:
    10458737
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Mechanisms of Natural Killer Cell Clearance of SIV from Lymphoid Follicles
淋巴滤泡自然杀伤细胞清除 SIV 的机制
  • 批准号:
    10305659
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Mechanisms of Natural Killer Cell Clearance of SIV from Lymphoid Follicles
淋巴滤泡自然杀伤细胞清除 SIV 的机制
  • 批准号:
    10529270
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Natural killer cell receptor-expressing B cells as regulators of mucosal immunity in SIV infection
表达自然杀伤细胞受体的 B 细胞作为 SIV 感染粘膜免疫的调节剂
  • 批准号:
    10451069
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Antigen-Specific NK Cell Memory Against SIV and HIV Vaccines
针对 SIV 和 HIV 疫苗的抗原特异性 NK 细胞记忆
  • 批准号:
    10408910
  • 财政年份:
    2021
  • 资助金额:
    $ 40.25万
  • 项目类别:
Natural killer cell receptor-expressing B cells as regulators of mucosal immunity in SIV infection
表达自然杀伤细胞受体的 B 细胞作为 SIV 感染粘膜免疫的调节剂
  • 批准号:
    9927204
  • 财政年份:
    2019
  • 资助金额:
    $ 40.25万
  • 项目类别:
Antigen-Specific NK Cell Memory Against SIV and HIV Vaccines
针对 SIV 和 HIV 疫苗的抗原特异性 NK 细胞记忆
  • 批准号:
    9405715
  • 财政年份:
    2017
  • 资助金额:
    $ 40.25万
  • 项目类别:

相似海外基金

Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver Disease
干扰素-γ/白介素-12 轴在代谢性肝病中的作用
  • 批准号:
    10735419
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Selective targeting of a Rho GTPase mutant for peripheral T cell lymphoma treatment
选择性靶向 Rho GTPase 突变体治疗外周 T 细胞淋巴瘤
  • 批准号:
    10721439
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Differentiation and function of transitional monocytes in cancer metastasis to the lung
移行单核细胞在癌症肺转移中的分化和功能
  • 批准号:
    10748569
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Emerging role of tumor-derived exosomes in immune modulation and breast cancer health disparity.
肿瘤源性外泌体在免疫调节和乳腺癌健康差异中的新作用。
  • 批准号:
    10726647
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
Dissecting the Differential Impacts of Toll-like Receptor 9 Agonism on the Capacity of Human Natural Killer Cells to Mediate Target Cell Killing
剖析 Toll 样受体 9 激动剂对人类自然杀伤细胞介导靶细胞杀伤能力的不同影响
  • 批准号:
    10730451
  • 财政年份:
    2023
  • 资助金额:
    $ 40.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了